| abstract |
The invention is directed to compounds that are P2X 7 antagonist and have the formula (I) or (II) n n n n n n n n n n n n or a pharmaceutically acceptable salt, prodrug, salt of a prodrug or a combination thereof, wherein R 1 , R 2 , and R 3 are defined in the specification. The invention is also directed to a method of selectively inhibiting P2X 7 activity comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula (III), (IV) or (V) n n n n n nwherein R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are defined in the specification. |